<DOC>
	<DOCNO>NCT01458717</DOCNO>
	<brief_summary>Previous report suggest benefit neoadjuvant chemoradiation treatment borderline resectable pancreas cancer . This study multicenter prospective randomize phase II/III study neoadjuvant chemoradiation gemcitabine patient borderline resectable pancreas cancer . The study design 2 arm , one upfront surgery neoadjuvant chemoradiation therapy .</brief_summary>
	<brief_title>Neoadjuvant Chemoradiation Patients With Borderline Resectable Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>&gt; 18 year old &lt; 75 year old ECOG 02 biopsy proven adenocarcinoma pancreas history previous chemotherapy borderline resectable pancreas cancer distant metastasis WBC least 3,000/mm3 absolute neutrophil count least 1,500/mm3 , Platelet count least 125,000/mm3 Bilirubin less 2.5 mg/dL AST le 5 time upper limit normal Creatinine great 1.5 time upper limit normal informed consent history previous chemotherapy history radiation &gt; 25 % area bone marrow stage unspecified , distant metastasis , recurrent pancreas cancer history malignant neoplasm ( except stage 0 cancer , skin situ cancer except malignant melanoma ) . Patients NED 5 year treatment malignant neoplasm candidate study pregnant , breastfeed patient uncontrolled active infection uncontrolled cardiopulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>pancreas</keyword>
	<keyword>cancer</keyword>
	<keyword>borderline resectable</keyword>
	<keyword>locally advanced</keyword>
	<keyword>resectability</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>radiation</keyword>
	<keyword>chemoradiation</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>survival</keyword>
	<keyword>prognosis</keyword>
	<keyword>recurrence</keyword>
	<keyword>response rate</keyword>
</DOC>